[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349337-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349337-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-novel-protein-markers-and-therapeutic-targets-for-common-urological-cancers-by-integrating-large-scale-human-plasma-proteome-with-the-genome","Identification of novel protein markers and therapeutic targets for common urological cancers by integrating large-scale human plasma proteome with the genome","","Circulating proteome profiling is treated as a primary source of biomarker and drug-target candidates for common urological cancers. Large-scale Mendelian randomization is used to prioritize plasma proteins involved in bladder cancer, prostate cancer, renal cell carcinoma, and testicular cancer, using cis-pQTLs from genome-wide association studies and colorectal analyses including colocalization and summary-data MR. Bulk RNA-seq, single-cell expression, protein–protein interaction, and druggability evaluation further validate findings, including causal evidence for specific proteins.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-novel-protein-markers-and-therapeutic-targets-for-common-urological-cancers-by-integrating-large-scale-human-plasma-proteome-with-the-genome/349337/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-novel-protein-markers-and-therapeutic-targets-for-common-urological-cancers-by-integrating-large-scale-human-plasma-proteome-with-the-genome/349337.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study?","Question",{"text":63,"@type":64},"To identify plasma protein markers and therapeutic targets for common urological cancers by integrating large-scale human plasma proteome data with genomic information.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were candidate protein–cancer associations evaluated?",{"text":68,"@type":64},"Cis-protein quantitative trait loci were derived from large-scale plasma proteome GWAS data, followed by colocalization analysis and summary-data MR to assess robustness.",{"name":70,"@type":61,"acceptedAnswer":71},"Which proteins showed the strongest causal evidence?",{"text":72,"@type":64},"MR and colocalization analyses supported GSTM4 for bladder cancer and SOD2 and CHMP2B for prostate cancer as causal markers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349337,1790471719,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nIdentification of novel protein markers and therapeutic targets for common urological cancers by integrating large-scale human plasma proteome with the genome  \nXinyi Lyu1,2,6, Liao Peng1,2,6, Yang Fan1,2,6, Yang Xiong3, Xueyuan Xu1,2, Jiawei Chen1,2, Mengzhu Liu1,2, Yuanzhuo Chen1,2, Chi Zhang1,2, Shiqin Yang1,2, Sihong Shen1,2, Jie Zhang1,2, Xiao Zeng1,2, Hong Shen1,2, Feng Qin3􀀍, Yifei Lin4,5􀀍 & Deyi Luo1,2􀀍  \nConsidering that the circulating proteome represents a primary source of candidate biomarkers and therapeutic targets, we conducted a large-scale Mendelian randomization (MR) study to identify plasma proteins potentially involved in the pathogenesis and treatment of common urological cancers (UCs), including bladder cancer (BC), prostate cancer (PC), renal cell carcinoma (RCC), and testicular cancer (TC). Cis-protein quantitative trait loci (cis-pQTLs) were derived from two large-scale genomewide association studies (GWASs) of plasma proteomes. GWAS for UCs were obtained from FinnGen and pan-UKBB meta-analysis, FinnGen and UK Biobank. Colocalization analysis and summary databased MR (SMR) were performed to evaluate the robustness of the associations. Further evaluations involved Bulk RNA-seq differential expression and single cell-type expression analysis, protein–protein interaction, and druggability evaluation. For BC, we identified four protein markers: one associated with increased risk (PSCA) and three with decreased risk (GSTM1, GSTM3, GSTM4), which are mainly expressed in pericyte, urothelial, and NK cells in bladder tumors. Regarding PC, we found 15 protein markers: seven linked to increased risk (AGER, ALAD, CHMP2B, PEX14, ZG16B, PPP1R14A, SERPINA3) and eight to decreased risk (BTN2A1, CEACAM21, DNAJB9, MSMB, PYGL, HLA-E, SOD2, TOR1AIP1), enriched in epithelial cells, monocytes/macrophages in prostate tumors. The strongest evidence from MR and colocalization analyses supported GSTM4 (BC), SOD2 and CHMP2B (PC) as causal markers. Notably, seven identified proteins have been previously targeted by drugs for other cancers and immune disorders, indicating their potential therapeutic relevance in UCs. This study highlights several proteins with predictive value for BC and PC risk and supports their utility in biomarker discovery and drug development.  \nKeywords Bladder cancer, Prostate cancer, Proteome-wide Mendelian randomization, Biomarker, Drug target  \nWith the global population growth and the increasing aging of societies, the incidence and prevalence of cancer are showing an upward trend. Among the common types of cancer, urological cancers (UCs) account for 13.1% of newly diagnosed cancer cases and 7.9% of overall cancer mortality1. UCs encompass various malignancies, including bladder cancer (BC), prostate cancer (PC), renal cell carcinoma (RCC), and testicular cancer (TC), among others. Compared to other cancers, UCs comprise a heterogeneous group of malignancies  \n1Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.  \n2Pelvic Floor Diseases Center, Wuhou District, West China Tianfu Hospital, Sichuan University, Sichuan Province, No. 37 Guoxue Alley, Chengdu City, China. 3Department of Urology and Andrology Laboratory, West China Hospital, Sichuan University, Sichuan Province, China. 4 Department of Urology, Lab of Health Data Science, Innovation Institute for Integration of Medicine and Engineering, West China Hospital, Med-X Center for Manufacturing,Sichuan University, Chengdu, Sichuan, People’s Republic of China. 5Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA. 6Xinyi Lyu, Liao Peng, andYang Fan contributed equally to this study and should be considered as co-first authors. 􀀍 email: [qinfeng@scu.edu.cn](qinfeng@scu.edu.cn); [ylin@wchscu.edu.cn](ylin@wchscu.edu.cn); [luodeyi@scu.edu.cn](luodeyi@scu.edu.cn)  \n[www. nature.com/sc","cbCaioXn5HzKgBsK","https://ap.wps.com/l/cbCaioXn5HzKgBsK","pdf",2443030,14,"English","# Abstract\n## Study approach: plasma proteome and Mendelian randomization\n## Validation: colocalization, MR robustness, expression and interaction analyses\n## Findings: risk and protective protein markers\n## Clinical relevance: druggability and therapeutic targeting","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To identify plasma protein markers and therapeutic targets for common urological cancers by integrating large-scale human plasma proteome data with genomic information.\"},{\"question\":\"How were candidate protein–cancer associations evaluated?\",\"answer\":\"Cis-protein quantitative trait loci were derived from large-scale plasma proteome GWAS data, followed by colocalization analysis and summary-data MR to assess robustness.\"},{\"question\":\"Which proteins showed the strongest causal evidence?\",\"answer\":\"MR and colocalization analyses supported GSTM4 for bladder cancer and SOD2 and CHMP2B for prostate cancer as causal markers.\"}]","Identification of novel protein markers and therapeutic targets for common urological cancers by integrating large-scale human plasma proteome with the genome | PDF",1790082865,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5951a09b65db1dc5558461b5aeffad9.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d8206273ae055ef5309365897d1b996.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53d6519aad675fedfd39f5c216d6e17e.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8995884136a794f4ee99ba4bacd98ea0.webp",980,1287]